Sign in

    Eli Merle

    Senior Analyst at UBS

    Eliana Merle is a Senior Analyst at UBS specializing in biotechnology and pharmaceuticals equity research, where she covers companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals. She is recognized for her thorough analysis and accurate calls, as reflected in successful stock ratings that include well-timed Buy recommendations and precise price target adjustments. Merle began her analyst career in the life sciences sector and has built a strong track record through her roles at UBS and prior research positions, consistently earning positive recognition in industry reports and platforms for her performance. She holds advanced professional credentials typical for equity analysts, including securities licenses and FINRA registration.

    Eli Merle's questions to ARVINAS (ARVN) leadership

    Eli Merle's questions to ARVINAS (ARVN) leadership • Q2 2025

    Question

    Tejas, on behalf of Eli Merle, asked for more details on the preclinical data for the KRAS program expected later in the year and how that might inform expectations for the Phase 1 trial of ARV-806.

    Answer

    CSO Angela Cacace detailed that upcoming preclinical data will highlight ARV-806's differentiation from inhibitors, its combinability with EGFR-targeted agents, and its ability to overcome resistance mechanisms. She also mentioned compelling data from the oral pan-KRAS program will be shared, including its potential for better combinability with immuno-oncology agents compared to pan-RAF inhibitors. This strong preclinical profile is driving investigator interest in the ongoing clinical trial.

    Ask Fintool Equity Research AI